Skip to content
ALS News Today logo Newsletter
Newsletter
  • About ALS
    What is ALS?
    Causes and risk factors
    Diagnosis
    Symptoms
    • Speech problems
    • Breathing and swallowing
    • Pseudobulbar affect
    Types of ALS
    • Familial ALS
    • Sporadic ALS
    Treatments
    • Approved treatments
    • Experimental treatments
    • Non-drug treatments
  • Living with
    Living with ALS
    Mental health
    Diet
    Exercise
    Aids and adaptations
  • Community
    Columns
    • Joyful Sorrow — Kristin Neva
    • Living Well With ALS — Dagmar Munn
    • Thunder Road — Juliet Taylor
    Archived columns
    • OutSpoken — James Clingman
    • The Mighty Mind — Rachel Doboga
    In memoriam
    • Notes From the ALS Front — Rick Jobus
  • News
  • Forums
  • Resources
    Advocacy partners
  • What can we help you find today?

  • Social Clips
  • Last Week’s Top-3 Most Read Posts On ALS

Last Week’s Top-3 Most Read Posts On ALS

admin avatar

by admin | January 11, 2016

Share this article:

Share article via email
  • Share on Facebook
  • Share on Twitter
  • Share on Reddit
  • Share via Email

news_8-22

Read the Articles Here:

Dysfunctional ALS Patient Skin-Derived Muscle Neurons Rescued by Kenpaullone

ALS and Other Neurological Disorders May Benefit from Prions Created in Lab

Genervon’s GM604 May Slow Disease Progression in ALS Patients

Print This Page

Tags

Genervon, Genervon Biopharmaceuticals, gm604, most read

Recent Posts

  • QRL-101 reduces motor-neuron hyperexcitability in ALS trial
  • COYA 302 trial in ALS expands to Canada after regulatory nod
  • Qalsody shows long-term benefits in some SOD1-ALS patients: Study
  • A letter to my newly diagnosed self
  • Holding on to possibility while living with ALS


Recommended reading

The words
January 5, 2026 News by Steve Bryson, PhD

COYA 302 trial in ALS expands to Canada after regulatory nod

A researcher uses a microscope in a laboratory alongside a rack of test tubes and a beaker.
January 2, 2026 News by Michela Luciano, PhD

Qalsody shows long-term benefits in some SOD1-ALS patients: Study

banner for
December 30, 2025 Columns by Dagmar Munn

A letter to my newly diagnosed self

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2026 All rights reserved.